HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.

AbstractBACKGROUND:
Systemic chemotherapies are associated with limited response rates and significant toxicity in patients with malignant digestive endocrine tumors (DET). Preliminary studies have reported interesting results with temozolomide in patients with DET.
AIM:
It was the aim of this study to assess the efficacy and safety of temozolomide in patients with malignant DET.
PATIENTS AND METHODS:
Twenty-one patients, median age 61 years (range 56-77), with metastatic well-differentiated DET were retrospectively studied. All patients except 1 had received prior treatment (hepatic resection, chemotherapy). All patients had progressive disease in the 3 months prior to entry into the study. Temozolomide was administered at doses of 200 mg/m(2) daily for 5 days, every 28 days. Treatment was assessed for safety, progression-free and overall survival.
RESULTS:
The median number of temozolomide cycles was 5 (range 2-15). Grade 3 hematological toxicity occurred in 5 patients. There were no toxic deaths. According to the Response Evaluation Criteria in Solid Tumors criteria, partial response and stabilization were obtained in 1 (5%) and 17 patients (81%), respectively. The median time to progression was 9 months (range 3-26). The 1-year progression-free survival and overall survival were 42 and 77%, respectively.
CONCLUSION:
Temozolomide is a well-tolerated oral chemotherapy in patients with malignant DET, including those who have already received treatment. In patients with progressive disease, temozolomide controls tumor progression in 86% of cases.
AuthorsFrédérique Maire, Pascal Hammel, Sandrine Faivre, Olivia Hentic, Lorena Yapur, Béatrice Larroque, Anne Couvelard, Magaly Zappa, Eric Raymond, Philippe Lévy, Philippe Ruszniewski
JournalNeuroendocrinology (Neuroendocrinology) Vol. 90 Issue 1 Pg. 67-72 ( 2009) ISSN: 1423-0194 [Electronic] Switzerland
PMID19521065 (Publication Type: Journal Article)
Copyright2009 S. Karger AG, Basel.
Chemical References
  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide
Topics
  • Aged
  • Analysis of Variance
  • Antineoplastic Agents, Alkylating (adverse effects, therapeutic use)
  • Carcinoid Tumor (drug therapy)
  • Dacarbazine (adverse effects, analogs & derivatives, therapeutic use)
  • Digestive System Neoplasms (drug therapy, mortality)
  • Disease Progression
  • Endocrine Gland Neoplasms (drug therapy, mortality)
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Retrospective Studies
  • Temozolomide
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: